从实验室到临床：推进KIM-1作为临床决策工具的应用.pdf

1、From Bench to Bedside:Advancing KIM-1 as a Tool for Clinical Decision-MakingWenxin(Vincent)Xu,MDAssistant Professor of MedicineDana-Farber Cancer InstituteDisclosuresResearch funding:DOD CDMRP KCRP AcademyASCO/Conquer Cancer FoundationDF/HCC Kidney Cancer SPOREOncohost(paid to institution)Merck(paid

2、 to institution)ArsenalBio(paid to institution)Scientific advisory board/consulting:Jazz Exelixis Aveo Xencor Merck Eisai Celdara DecipheraThanks and AcknowledgementsClara Steiner,MDMarc Machaalani,MDLiliana Ascione,MDPrateek Khanna,MDToni Choueiri,MDSrini R.Viswanathan,MD PhDLisa P.Henske,MDMatthew

3、 L.Freedman,MDSabina Signoretti,MDRizwan Romee,MDGrace Birch,PhDFuguo Liu,PhDWanling Xie,MSSamuel Niman,MSSaurabh Gupta,PhD Sai Vemula,PhDFundingMahrukh Huseni,MSRomain Banchereau,PhDYehonatan Elon,PhDMichal Harel,PhDDavid F.McDermott,MDDavid Einstein,MDXiaowen Liu,PhDJoseph V.Bonventre,MD PhDTakaha

4、ru Ichimura,PhDOliver Jonas,PhDDavid Braun,MD PhDNirmish Singla,MD MScPhillip Pierorazio,MDNaomi B.Haas,MDPaul Brennan,PhDAdam Dicker,MD PhDMonty Pal,MDPavlos Msaouel,MD PhDChad Tang,MDFunding for KIM-1 experiments from R01CA258442(PI:David F.McDermott)Andrew Simmons,PhDVenugopal Valmeekam,PhDEXCLUS

5、ION ZONEFunding supportMentorshipCareer developmentCollaborationEXCLUSION ZONEKIM-1/TIM-1 is overexpressed in RCC and shed into the circulationXCLUSION ZONEKIM-1/TIM-1 is overexpressed in ccRCC and papillary RCC but not in healthy kidneys90 kDa ectodomain is detectable in urine and plasmaHan WK,Alin

6、ani A,Wu CL,Michaelson D,Loda M,McGovern FJ,Thadhani R,Bonventre JV.J Am Soc Nephrol.2005 Apr;16(4):1126-34.Among 190 RCC patients,KIM-1 was elevated in banked plasma up to 5 years prior to diagnosis vs matched controlsScelo G,Muller DC,Riboli E,Johannson M,Cross AJ,Vineis P Khanna P,Bonventre JV,Sa